Asset Management One Co. Ltd. boosted its stake in Insulet Corporation by 29.0% during the third quarter, increasing its holdings by 8,622 shares to 38,401 shares, representing approximately 0.05% of outstanding stock and a position valued at $11.86 million as of the latest SEC filing. Concurrently, a cohort of smaller hedge funds adjusted their positions: True Wealth Design LLC raised its stake by 288.0% to 97 shares, Kozak & Associates Inc. initiated a new position, Golden State Wealth Management LLC expanded by 202.9% to 103 shares, Trust Co. of Toledo NA OH entered with a new holding, and Osterweis Capital Management Inc. established a position, collectively underscoring growing institutional interest in Insulet’s tubeless insulin delivery business.

A total of twenty-four sell-side analysts cover Insulet, with one assigning a Strong Buy rating, twenty-one issuing Buy ratings and two recommending Hold, yielding an average consensus of “Moderate Buy.” The company’s current average implied future share value—excluding specific price targets—reflects analysts’ upward revisions over recent months, including multiple firms raising their outlook following better-than-expected quarterly results. Reports issued since October have largely reinforced a positive view of Insulet’s growth trajectory.

In its latest quarter, Insulet reported earnings per share of $1.24, beating consensus estimates by $0.11, and achieved revenue of $521.7 million, up 29.9% year-over-year. The company’s net margin stood at 9.76% with a return on equity of 24.36%, while its P/E ratio was approximately 85 and its P/E/G ratio was 1.58. Balance sheet metrics include a current ratio of 2.87 and a debt-to-equity ratio of 0.68, reflecting solid liquidity and moderate leverage as the firm continues to scale commercialization of its Omnipod platform globally.